Company code: Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) company abbreviation: Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) Heilongjiang Zbd Pharmaceutical Co.Ltd(603567)
Annual report for 2021
Important tips
1、 The directors and supervisors shall not be jointly and severally liable for any misrepresentation, omission or material misrepresentation of the company’s annual report, and the directors and supervisors shall not be jointly and severally liable for any misrepresentation, omission or material misrepresentation of the company’s annual report. 2、 All directors of the company attended the board meeting. 3、 Zhongzhun Certified Public Accountants (special general partnership) issued a standard unqualified audit report for the company. 4、 Fang Tonghua, the person in charge of the company, Wang Lei, the person in charge of accounting, and Wang Lei, the person in charge of the accounting organization (Accounting Supervisor), declare that they guarantee the authenticity, accuracy and completeness of the financial report in the annual report. 5、 The profit distribution plan or the plan of converting accumulation fund into share capital in the reporting period adopted by the resolution of the board of directors
Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) plans to distribute cash dividends of 1.06 yuan (including tax) to all shareholders for every 10 shares based on the total share capital of 941963592 shares on December 31, 2021, with a total amount of 9984814076 yuan. The accumulated remaining undistributed profit of the parent company is 284022461968 yuan, which is carried forward to the next year. In 2021, no shares will be given and no capital reserve will be converted into share capital. 6、 Risk statement of forward-looking statements √ applicable □ not applicable
The forward-looking statements such as future plans and development strategies involved in this report do not constitute the actual commitment of the company to investors. Investors are reminded to pay attention to investment risks. 7、 Whether there is any non operational occupation of funds by the controlling shareholders and their related parties? VIII. Whether there is any external guarantee in violation of the specified decision-making procedures? IX. whether more than half of the directors cannot guarantee the authenticity, accuracy and integrity of the annual report disclosed by the company? X. major risk tips
During the reporting period, there were no particularly significant risks that had a material impact on the company’s production and operation. The company has elaborated various risks and countermeasures that the company may face in the process of production and operation in this report. Please refer to the “possible risks” in Section III Management Discussion and analysis. 11、 Others □ applicable √ not applicable
catalogue
Section 1 interpretation three
Section II Company Profile and main financial indicators 4 section III Management Discussion and Analysis Section 4 corporate governance Section 5 environmental and social responsibility 55 section VI important matters Section VII changes in shares and shareholders 69 Section VIII preferred shares 75 section IX relevant information of bonds 76 section x financial reporting seventy-seven
Accounting statements containing the signatures and seals of the legal representative, the person in charge of accounting and the person in charge of accounting institutions;
The catalogue of documents for future reference contains the original audit report sealed by the accounting firm and signed and sealed by the certified public accountant;
The texts of all company documents and the originals of announcements publicly disclosed on the website of Shanghai Stock Exchange and the media meeting the conditions specified by the CSRC during the reporting period.
Section I interpretation
1、 Interpretation in this report, unless the context otherwise requires, the following words have the following meanings: Interpretation of common words
The company, the company, Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) , Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) pharmaceutical, refers to Heilongjiang Zbd Pharmaceutical Co.Ltd(603567)
Hulin company
Jixi branch refers to Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) Jixi branch
Trading Center refers to Bozhou traditional Chinese medicine commodity trading center Co., Ltd
Harbin Zhenbao refers to Harbin Zhenbao Pharmaceutical Co., Ltd
Heiyi trade refers to Heilongjiang Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) Pharmaceutical Trade Co., Ltd
Controlling shareholder and Hulin Chuangda refer to Heilongjiang Chuangda Group Co., Ltd., the controlling shareholder of the company
Hulin longpeng refers to Hulin longpeng Investment Center (limited partnership), the major shareholder of the company
Tress refers to Zhejiang tress Pharmaceutical Co., Ltd
Mat refers to the monthly rolling annual sales trend, which is a calculation method. The calculation method is the data of the whole year before the calculation time.
Shanghai stock exchange refers to Shanghai Stock Exchange
It refers to the integration of medical resources in the same region. Usually, the medical consortium refers to a medical consortium composed of tertiary hospitals, secondary hospitals, community hospitals and village hospitals in a region. The purpose is to solve the problem that it is difficult for people to see a doctor.
According to the geographical location, service population, setting and layout of existing medical and health institutions, each county establishes several (generally 1 medical community refers to – 3) with county-level medical institutions as the leader, several other county-level medical institutions and township health centers Community health service center is a “close medical community” of member units.
The reporting period refers to the period from January 1 to December 31, 2021
Section II Company Profile and main financial indicators
1、 Company information
Chinese name of the company Heilongjiang Zbd Pharmaceutical Co.Ltd(603567)
Chinese abbreviation of the company Heilongjiang Zbd Pharmaceutical Co.Ltd(603567)
The foreign language name of the company is heilongjiangzbd Pharmaceutical Co, Ltd.
The abbreviation of the company’s foreign name ZBD
Legal representative of the company: Fang Tonghua
2、 Contact person and contact information
Secretary of the board of directors and securities affairs representative
Name: Zhang Haiying, Wang Zhenyu
Contact address: No. 8, Yantai 1st Road, Pingfang District, Harbin, Heilongjiang Province No. 8, Yantai 1st Road, Pingfang District, Harbin, Heilongjiang Province
Tel: 045186811969
Fax 045187105767
E-mail [email protected]. [email protected].
3、 Basic information
Registered address: No. 72, Hongxing street, Hulin Town, Hulin City, Jixi City, Heilongjiang Province
Office address: No. 8, Yantai 1st Road, Pingfang District, Harbin, Heilongjiang
The postal code of the company’s office address is 150060
Company website http://www.zbdzy.com.
E-mail [email protected].
4、 Information disclosure and preparation location
The media name and website of the annual report disclosed by the company include Shanghai Securities News, China Securities News, securities times and Securities Daily
Website of the stock exchange where the company discloses the annual report www.sse com. cn.
The company’s annual report is prepared at the office of the board of directors of the company
5、 Company stock profile
Company stock profile
Stock type stock exchange stock abbreviation stock abbreviation before stock code change
A-share Shanghai Stock Exchange Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) none
6、 Other relevant information
Name of accounting firm employed by the company: zhongzhun Certified Public Accountants (special general partnership)
Office address (domestic) 4th floor, building 22, Shouti South Road, Haidian District, Beijing
Name of signature accountant: Liu Feifei, Zhang Yanwei
Name: Huarong Securities Co., Ltd
During the reporting period, 16 / F, the recommendation agency insurance building, whose office address is The People’S Insurance Company (Group) Of China Limited(601319) Shou, No. 18, Chaoyangmen North Street, Chaoyang District, Beijing
Names of the sponsor representatives signing: Ding Li and Qiao Xude
The period of continuous supervision is from November 11, 2021 to December 31, 2022
7、 Main accounting data and financial indicators in recent three years (I) main accounting data
Unit: yuan currency: RMB
Compared with the previous period
The main accounting data will increase from 2021 to 2020 year-on-year in 2019
Minus (%)
Operating income 412681389618340374728097 21.24329185597018
Net profit attributable to shareholders of listed companies 3320996729643628578559 -23.8840864886438
Net profit attributable to shareholders of listed companies after deducting non recurring profits and losses of 7923653687, 35893355659 -77.92, 34134537177
Net cash flow from operating activities -4339369409415517802516 -379.6422092286130
Comparison at the end of the period
